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Negatively skewed survival data arise occasionally in public health fields and in
statistical research. Standard distributions such as the exponential, generalized
F, generalized gamma, Gompertz, log-logistic, lognormal, Rayleigh, and Weibull
distributions are not always well suited to this data. The primary goal of this
dissertation is to find a viable alternative for modeling negatively skewed survival
data such as the time to first remission for pediatric patients with frequently relapsing
or steroid dependent nephrotic syndrome.
We begin with a brief introduction of survival analysis and the nature of pediatric
nephrotic syndrome. A meta-analysis on atopy and pediatric nephrotic syndrome using
worldwide studies is performed. We introduce the reflected-shifted-truncated-gamma
(RSTG) distribution as an alternative model for survival data whose event times
arise from a negatively skewed distribution. Explicit expressions are provided for
the mean, variance, hazard function, survival function and quantile function of the
RSTG distribution. A simulation study verifies the consistency of maximum likelihood
estimates of model parameters. Using maximum likelihood methods, we compare the
RSTG distribution to the exponential, generalized F, generalized gamma, Gompertz,
log-logistic, lognormal, Rayleigh, and Weibull distributions for modeling negatively
skewed complete (uncensored) data, right-censored data and interval-censored data
using well-known data sets. We then apply the RSTG distribution to pediatric
nephrotic syndrome data from the Clinical Data Warehouse from Health Sciences of
South Carolina and from the Robert Wood Johnson Medical School in New Jersey
using covariate adjusted accelerated failure time (AFT) models with and without
vi
frailty. We include a brief example of the RSTG distribution applied to a 1972 study
on diabetic retinopathy.
Our research shows that the RSTG distribution is superior to the eight aforemen-
tioned distributions for modeling negatively skewed survival data. The results from
applications of this distribution and future goals are discussed.
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Survival analysis is a statistical method for data analysis in which the outcome variable
is the time to the occurrence of an event (John P. Klein and Moeschberger, 2003).
Time-to-event data, or survival time data, is common in medical research. Examples
of events of interest include relapse of cancer, remission of nephrotic syndrome,
recurrence of a tumor, development time from HIV infection to an AIDS diagnosis
for HIV patients, or death. The definition of event time should be made clear at
the start of the study. In studying the nature of the disease, for example, we must
specify whether the time of origin is when the symptoms start, when the biological
identification of the disease happens, or when the diagnosis is made. The time scale
and the origin of the event must also be identified.
Survival times can either be censored or uncensored. Uncensored observations are
commonly referred to as complete data and are observed exactly. Censored observations
are not observed exactly and can be left-censored, right-censored, or interval-censored.
If the event of interest occurs prior to the start of a study, the observation time is
left-censored. An observation is right-censored if a subject withdraws from a study or
if the study ends before the event of interest has occurred. An observation is interval-
censored if the event of interest is only known to have occurred within a given interval
of time. In this dissertation, we will assume that all censoring is non-informative, or
unrelated to the study.
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Survival analysis techniques make use of the incomplete data collected from
censored event times. The event times are subject to random variation, and, like any
random variables, form a distribution (Lee and Wang, 2003). The distribution of
survival times is usually characterized by three functions: (1) the survival function, (2)
the probability density function, and (3) the hazard function. These three functions
are mathematically equivalent. If one of them is known, the other two can be derived.
1.1.1 Basics of Survival Analysis
A function f(u) is a probability density function (pdf) of a random variable U if
and only if





The cumulative distribution function, or cdf, of a random variable U , denoted
by F (u), is defined by





The area under the curve of f(u) can give interval probabilities. For example,
P (a < U < b) =
b∫
a
f(u)du = F (b) − F (a). If f(u) is continuous, the Fundamental
Theorem of Calculus gives the additional relationship
d
du
F (u) = f(u).
The survival function gives the probability that a person survives longer than
some specified time t. Let T denote a nonnegative random variable whose individual
values t represent the time to an event of interest. The survival function of T , denoted
by S(t), is given by S(t) = P (T > t), 0 < t < ∞. Theoretically, the survival
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function is a non-increasing continuous function such that S(0) = 1 and S(∞) = 0. If




f(u)du, 0 < t <∞. Note that S(t) = 1− F (t).
The hazard function gives the instantaneous potential per unit time for the
event to occur, given that the event has not occurred up to time t. It is given by
h(t) = lim
∆t→0+




P (t ≤ T < t+ ∆t) ∩ P (T ≥ t)




P (t ≤ T < t+ ∆t)
∆t ·
1
P (T ≥ t)
= lim
∆t→0+
F (t+ ∆t)− F (t)
∆t ·
1
P (T ≥ t)
= d
dt
F (t) · 1
P (T ≥ t)
= f(t)
S(t) ,
where 0 < t <∞. The hazard function is sometimes called a conditional failure rate
(Kleinbaum and Klein, 2006).




0 < t <∞,




















Therefore, we can express H(t) =
t∫
0
h(u)du = − logS(t).
1.1.2 Goals of Survival Analysis
The goals of survival analysis include estimation of the survival and/or hazard functions,
comparison of the survival and/or hazard functions, and assessment of the relationship
between explanatory variables (covariates) and survival time. Survival data consists
of a time of event, generally denoted by ti, the values of any covariates that are




1 if the event of interest is observed
0 if the event of interest is not observed
.
One of the first steps in analyzing survival data is presenting a numerical or graphical
summary of the data. This summary may be used to suggest a survival model for
the data. Non-parametric models are widely used models in the literature. The most
common of these, the Kaplan-Meier estimator of the survival function, is actually
a step function in which the estimated survival probabilities are constant between
adjacent event times and decrease with each event time. If there is no censoring,
the function is simply a step function equal to the proportion surviving an instant
after time t. One common use of the Kaplan-Meier estimated survival function is to
compare the survival probabilities of two groups. A major disadvantage of this type
of model is its inability to estimate survival probabilities at all time points.
The Cox proportional hazards (PH) model is most common for modeling
survival data to assess the effect of covariates on survival probabilities. The Cox model
is often deemed as semi-parametric because no assumptions are made concerning a
baseline hazard function; consequently, no assumptions are made on the distribution
of the survival times. It is assumed that all subjects in the study have a common
baseline hazard; thus, the ratio of the hazards of two subjects is some constant that is
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independent of time. The model is specified as h(t) = h0(t)eβx , where 0 < t < ∞,
x = (x1, x2, . . . , xn) represents the vector of covariates of interest, eβ represents the
hazard ratio between groups and h0(t) represents the baseline hazard function. An
advantage of this model is its considerable flexibility since full specification of the
baseline hazard function is not required. Fully parametric proportional hazards
models, which assume that the baseline hazard function can be fully parametrized,
can also be used. A disadvantage of both the semi-parametric and the fully parametric
proportional hazards models is the necessity of the assumption of proportional hazards,
which may not be valid for some time-to-event data. Alternative versions of the
standard Cox proportional hazards model can be used when the proportional hazards
assumption is not satisfied. These include the time dependent Cox model and the
stratified Cox model. The time dependent Cox model introduces a time dependent
variable to accommodate the variable that does not satisfy the proportional hazards
assumption. The stratified Cox model allows the model to be stratified on the variable
that does not satisfy the proportional hazards assumption. Either model can limit
the overall interpretability of the parameters as the variable that has been modified
to accommodate the proportional hazards assumption is no longer interpretable.
The accelerated failure time (AFT) model is a general parametric model for
survival data that has been used more frequently in recent years. In the accelerated
failure time model, covariates have a direct effect on the survival time while in the
proportional hazards model, the covariates have a multiplicative effect on the hazard
function. The covariate effects change the timescale in the AFT model and, therefore,
accelerate or decelerate the time to the event of interest. The general model for
accelerated failure time is S(t) = S0(γt) where S0(t) represents a baseline survival
function and γ represents an acceleration factor. Parametric AFT models provide a
useful alternative to the PH model when modeling survival data (Wei, 1992). The
AFT approach models the survival times directly and gives summary measures that
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are interpreted in terms of the survival curve (Hutton and Monaghan, 2002; Orbe,
Ferreira, and Núñez-Antón, 2002; Patel, Kay, and Rowell, 2006; Pourhoseingholi et al.,
2007). Common applications of the parametric AFT model in the literature include
aging research (Swindell, 2009), kidney transplant survival (Lambert, Collett, Kimber,
and Johnson, 2004), and coronary heart disease (Chen, Zhang, and Zhang, 2013). The
parametric AFT model can incorporate a wide range of survival distributions.
One of the main advantages of using parametric survival models is the complete
specification of the survival, hazard, and density functions. Also, the parametric
model is smooth and continuous. The parametric approach can estimate “between
point” probabilities whereas the non-parametric approach can only give stepwise-
estimates using the time points actually reported in the study. Nevertheless, parametric
survival models are historically not as popular as non-parametric or semi-parametric
models. Derivations of the survival and hazard functions of parametric models may be
computationally intensive, and the true nature of a distribution may be hard to verify
in practice. However, it is generally agreed that if a parametric form can capture
the true nature of data, the results and implications will be far more precise (Collett,
2015).
1.2 Pediatric Nephrotic Syndrome
“Idiopathic” nephrotic syndrome, or nephrotic syndrome that arises spontaneously, is
a rare disease syndrome that commonly has a relapsing course. Pediatric idiopathic
nephrotic syndrome, a condition listed in the Rare Diseases Clinical Research Network,
a division of the National Institute of Health, is a condition that about 2-7 of
every 100,000 children are living with today (Kerlin, Haworth, and Smoyer, 2014).
According to the National Institute of Diabetes and Digestive and Kidney Diseases,
pediatric nephrotic syndrome is a set of signs or symptoms that may indicate kidney
dysfunction. The nephrotic syndrome describes a triad of hypoalbuminemia (low levels
6
of protein in the blood), edema (swelling resulting from buildup of salt and water),
and hyperlipidemia (high levels of protein in the urine)(Saleem, 2013). Other signs
include less frequent urination and weight gain from excess fluid. Pediatric nephrotic
syndrome can occur at any age but most commonly occurs between the ages of 112
and 5 years of age and affects boys more than girls (Childhood Nephrotic Syndrome,
2016).
Prior to the initiation of steroid treatment in the 1960s, the risk of morbidity
and mortality from pediatric nephrotic syndrome was extremely high (Soyka, 1967).
It is now the widely accepted standard that the best first line treatment for the
initial diagnosis of idiopathic nephrotic syndrome in children is a high dosage corticos-
teroid treatment (Fomina, Pavlenko, Englund, and Bagdasarova, 2011; Noer, 2005;
Richardson, 2012; Pasini et al., 2015). However, prolonged and repeated corticosteroid
treatment may induce serious steroid toxicity such as growth retardation and cataracts
(A. Takeda, Matsutani, Niimura, and Ohgushi, 1996). Other significant side effects of
these treatments include high blood pressure, increased appetite and significant weight
gain, restlessness, behavioral changes, reduction in the body’s ability to fight infection,
cosmetic side effects such as increased hair growth on the face or body, swollen or
painful gums, and, less commonly, painful urination (CVS Pharmacy, 2016).
In general, if a relapse occurs several times within a given time frame, the diagnosis
of nephrotic syndrome is further classified as either steroid dependent (sometimes
referred to in earlier literature as steroid responsive) or frequently relapsing. In this
case, a second line of medication is introduced to reduce the risk of steroid toxicity
and to achieve a lasting remission. If a first remission is still not achieved within a
given time frame, the diagnosis becomes steroid resistant, and alternative treatment
methods are applied (Lombel, Gipson, and Hodson, 2013). Definitions of the common
classifications of pediatric nephrotic syndrome are given in Appendix A. Previous
findings suggest that the majority of pediatric patients will relapse after the initial
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remission. Thus, other medicines are studied to determine their effectiveness in
achieving and maintaining a remission for as long as possible (Fomina et al., 2011;
Mishra, Abhinay, Mishra, Prasad, and Pohl, 2013; A. Takeda et al., 1996). Current
treatment strategies in addition to the high dose of prolonged steroid treatment
include cyclophosphamide, chlorambucil, cyclosporine A, mycophenolate mofetil and
other immunosuppressive agents (Fomina et al., 2011). More recently, rituximab,
an intravenous drug used to treat rheumatoid arthritis and B-cell non-Hodgkin’s
lymphoma, has been used and is under study for the difficult-to-treat nephrotic
syndrome (Sinha et al., 2015).
Studies suggest that almost all proposed and currently used treatments carry
significant side effects (Latta, von Schnakenburg, and Ehrich, 2001; Iijima et al., 2002;
Tullus and Marks, 2013). Researchers urgently need to better understand the nature
of the disease and to identify specific risk factors that would foster better treatment
decisions. The pediatric patient diagnosed with frequently relapsing nephrotic syn-
drome or steroid dependent nephrotic syndrome provides a special challenge to the
parent and health care provider since the risk of adverse events from prolonged or
repeated medication is much higher.
1.2.1 Previous Findings and Methods
Much of the literature involving pediatric idiopathic nephrotic syndrome originates
in areas other than the U.S. In a recently documented multicenter retrospective
study, six pediatric nephrology units in Italy collected data and studied the regimens
for management of the disease (Pasini et al., 2015). This study highlights the vast
differences in treatment strategies and efforts to prevent acute complications from the
disease, while shedding light on many of the epidemiological, clinical, and laboratory
parameters of pediatric patients diagnosed with idiopathic nephrotic syndrome. Studies
have been conducted in Bangladesh (Sarker et al., 2012) with more concentration on
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age, socioeconomic status and rate of infection. A study of immunosuppressive agents
in pediatric nephrotic syndrome was also conducted in Australia (Durkan, Hodson,
Willis, and Craig, 2001).
Sixteen institutions in North America conducted a large cross sectional study on
patient reported outcomes with change in nephrotic syndrome relapse or remission
status (D. S. Gipson et al., 2013). According to a division of the U.S. National
Institute of Health, there are also several active or recruiting clinical trials for research
on pediatric nephrotic syndrome (Pediatric Nephrotic Syndrome, 2016). One of those
is a large scale observational cohort study known as INSIGHT (Insight into Nephrotic
Syndrome: Investigating Genes, Health and Therapeutics). It is currently studying
and recruiting patients in Canada (Hussain et al., 2013). Only five of the studies
listed by the U.S. National Institute of Health involve U.S data, and only one has
been completed with published results.
Literature suggests that relapses within the first year of diagnosis are highly
predictive of the subsequent course of the disease. This finding was confirmed in India
(Mishra et al., 2013), Japan (A. Takeda et al., 1996), China (Wang, Liu, Dai, Yang,
and Tang, 2005), Indonesia (Noer, 2005) and the Ukraine (Fomina et al., 2011). Other
factors, including gender, age at onset, and the tapering regimen for steroid therapy,
were found to be insignificant in predicting subsequent relapse. Numerous reports
have suggested an association between atopy and nephrotic syndrome (Thomson,
Stokes, Barratt, Turner, and Soothill, 1976; Meadow and Sarsfield, 1981; Rebien,
Müller-Wiefel, Wahn, and Schärer, 1981; Yap et al., 1983; Hilmanto, 2007; Abdel-
Hafez, Shimada, Lee, Johnson, and Garin, 2009). Past analysis efforts for pediatric
nephrotic syndrome have included basic univariate analyses, logistic regression, use
of the Kaplan-Meier survival model, and use of the Cox proportional hazards model.
These measures were taken to describe the overall characteristics of the patient, to
assess the relative contribution of factors affecting the relapse status of the patient,
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and to analyze the efficacy of various treatment strategies (ISKDC; Tarshish, Tobin,
Bernstein, and Edelmann, 1997; Constantinescu, Shah, Foote, and Weiss, 2000; Wang
et al., 2005; Debbie S. Gipson et al., 2009; Fomina et al., 2011; Ishikura et al.,
2012). Studies also assess predictors for and frequency of relapse (A. Takeda et al.,
1996; Fomina et al., 2011; Mishra et al., 2013; Sureshkumar, Hodson, Willis, Barzi,
and Craig, 2014). Gadegbeku et al. (2013) state that the ability to effectively treat
nephrotic syndrome is hindered by a lack of understanding of disease mechanisms and
lack of predictors to identify clinical course and therapeutic responsiveness.
For the pediatric patient whose diagnosis is frequently relapsing or steroid de-
pendent nephrotic syndrome, studies suggest that the time to initial remission is
significantly longer than those diagnosed with other, more manageable forms of the
disease, such as infrequently relapsing or non-relapsing nephrotic syndrome (Vivarelli,
Moscaritolo, Tsalkidis, Massella, and Emma, 2010; Yap, Han, Heng, and Gong, 2001;
Letavernier et al., 2008; Fujinaga, Hirano, and Nishizaki, 2011; Nakanishi et al., 2013;
Constantinescu et al., 2000; Harambat et al., 2013; Sureshkumar et al., 2014). No
prior studies address the possible effect of a covariate to accelerate or decelerate
the time to first remission. None of the literature to date has analyzed predictors
for remission using the accelerated failure time model. Furthermore, since there
are distinct geographical, economic, technological, and cultural differences between
the U.S. and other regions, researchers need to perform more studies on the U.S.
population.
1.3 Pediatric Nephrotic Syndrome Data Sources
1.3.1 South Carolina
Health Sciences of South Carolina (HSSC), the first statewide biomedical research
collaborative in the United States, has established a database that includes data
on pediatric nephrotic syndrome (Research, 2016). This statewide Clinical Data
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Warehouse (CDW) system is a part of its mission to improve the health of all South
Carolinians. The creation of the CDW and the data management platform support
the goal of significant growth in clinical trials and medical research by facilitating
collaboration across HSSC member organizations (Clinical Data Warehouse, 2016).
The data include demographics, visits/encounters, diagnoses, procedures, labs, and
medications. The database will contain 3.2 million patients of all ages with various
ailments and diseases across South Carolina. It includes longitudinal data files with
real time updates. Current data is reflective of 2004-2015. We obtained data on
pediatric nephrotic syndrome patients from this database for use in our analysis. All
permissions were obtained for data access and use.
1.3.2 New Jersey
The Robert Wood Johnson Medical School in New Brunswick, N.J. is one of the
nation’s leading comprehensive medical schools. Previously an academic unit of
the University of Medicine and Dentistry of New Jersey, Robert Wood Johnson
Medical School transferred to Rutgers University as part of the New Jersey Medical
and Health Sciences Education Restructuring Act, on July 1, 2013 (About RWJMS,
2016). Pediatric nephrologists from Robert Wood Johnson Medical School in New
Jersey performed a retrospective chart review of all pediatric patients with nephrotic
syndrome that were followed up for at least one year (Constantinescu et al., 2000).
The data collected at the initial diagnosis of NS included gender, race, age, hematuria
status, days to remission, and pattern of relapses in the first year after diagnosis. Data
necessary for the analysis were obtained from the study authors.
1.4 Dissertation Goals
In this dissertation, we concentrate on survival methods for modeling negatively
skewed data. Pediatric nephrotic syndrome is used as a motivating example for our
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research. We begin in Chapter 2 by assessing the relationship between atopy and
nephrotic syndrome using a meta-analysis of worldwide studies. We provide a brief
descriptive analysis of both the South Carolina pediatric nephrotic syndrome data
and the New Jersey data in Chapter 3. In Chapter 4, we develop the reflected-shifted-
truncated-gamma (RSTG) distribution for use in modeling negatively skewed data.
Also in Chapter 4, we provide explicit expressions for the mean, variance, hazard
function, survival function and quantile function of the RSTG distribution. We
estimate the model parameters by maximum likelihood methods based on complete,
right-censored and interval-censored survival data. We assess the performance and
verify the consistency of the maximum likelihood estimators of the RSTG distribution
by conducting a simulation study with various sample sizes, and we compare the
RSTG distribution to the exponential, generalized F, generalized gamma, Gompertz,
log-logistic, lognormal, Rayleigh, and Weibull distributions when modeling negatively
skewed data in three real data sets.
In Chapter 5, we use the RSTG distribution in an accelerated failure time model,
apply it to the pediatric nephrotic syndrome data and draw conclusions. We use the
RSTG distribution in an accelerated failure time model with frailty in Chapter 6.
Finally, we summarize our research and discuss future work in Chapter 7.
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Chapter 2
Atopy and Pediatric Nephrotic Syndrome: A
Meta-Analysis
2.1 Introduction
Pediatric nephrotic syndrome has been sporadically studied in many different countries
for over 30 years. An association between nephrotic syndrome and atopic activity
has been noted in multiple studies (studies 4-23 in Appendix B), but identification
of allergies as a specific risk factor was not always a primary goal of the study.
Furthermore, the definition of allergy/atopy was not standardized and the wide
heterogeneity in terminology used to define allergy could make results unclear.
Allergies are a common public-health concern. A proclivity to allergies may cause an
individual’s immune system to operate in a more heightened state than normal. Natural
mechanisms of the body that fight foreign antigens produce antibodies that may react
in other places in the human body. These reactions could cause adverse effects. For
example, the antibodies could bind to membranes in the kidneys, causing damage and
leakage that potentially leads to kidney disorders such as nephrotic syndrome (National
Institute of Health, 2014). Moreover, medications commonly used to treat nephrotic
syndrome work to suppress the immune system and might inadvertently suppress the
ability of the body to police the role of the antibodies (National Institute of Health,
2014). These medications, such as prednisone, chlorambucil, and cyclosporine, may
be nephrotoxic themselves.
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The connection between the pediatric nephrotic syndrome and atopy, or more
generally the immune system, requires further study. This study quantifies the
association between atopy and nephrotic syndrome by analyzing previous studies




Published reports involving pediatric nephrotic syndrome and atopy were acquired
from searches conducted from February 2014 to June 2014. The searches were
conducted using NIH (National Institutes of Health) registry of studies, the Cochrane
Collaboration, PubMed and PubMed Central, Embase, Google Scholar, Medline,
CDSR (Cochran Database of Systematic Reviews), NICE (National Institute for
Health and Care Excellence), Medscape and ProQuest. The following medical subject
headings and terms were used: nephrotic syndrome, pediatric nephrotic syndrome,
allergy, and atopy. Other sources were found in the references section of the retrieved
articles and from two pediatric nephrologists known to be actively involved with
pediatric nephrotic syndrome. 173 publications were obtained. No location, language
or time restrictions were applied.
2.2.2 Study Selection
Any study article that referenced a relationship between nephrotic syndrome in the
pediatric population and atopy was included in the first phase of study selection.
The pediatric population was limited to individuals between 0 and 18 years of age.
From the 20 studies selected in this phase, we excluded studies without adequate
information to calculate an odds ratio and corresponding 95% confidence interval,
studies that selected controls with regard to exposure status, and studies that included
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Articles identified (n=173)




Articles excluded after title or
brief abstract review (n=153)
Excluded:
- Insufficient information for
odds ratio (n=12)
- Data not extractable (n=1)
- Controls selected with regard
to exposure status (n=2)
Figure 2.1: Flow chart demonstrating studies chosen for the meta-analysis.
adults whose results could not be distinguished from the children’s results (studies
5-9, 11, 13-20, and 23 in Appendix B) (Figure 2.1).
2.2.3 Data Extraction
The following information was extracted from each study article: author, journal,
participant ages, location, year, ethnicity, sample size, study accrual period, disease
status at the time of investigation, study design, matching or adjustments, type of
NS studied, exposure/type of allergy studied, primary study goal, secondary study
goal, and statistics to calculate the odds ratio and corresponding confidence interval.
The exposure variable included any terms used to define and characterize atopy in
the studies, such as serum IgA, IgE, IgM and IgG levels, history of asthma, eczema,
urticaria, hay fever, common household allergens, and allergic rhinitis. The outcome
variable, nephrotic syndrome, was more uniformly defined and is consistent with
KDIGO (Kidney Disease–Improving Global Outcomes) and ISKDC (International
Study of Kidney Disease in Children) guidelines. Patients in selected studies were
identified as having some form of idiopathic nephrotic syndrome: frequently relapsing
(FRNS), steroid responsive (S.R.N.S) or minimal change disease (MCD). Steroid
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dependent (SDNS), S.R.N.S., and steroid sensitive (SSNS) are sometimes used in-
terchangeably in the literature although there are slight variations in the nature of
relapse for each group (Appendix A).
2.2.4 Statistical Assessment
Because of the limited number of studies, no subgroup analysis was conducted to
determine if the effect of allergy on nephrotic syndrome is consistent across the three
categories of the syndrome included in this analysis or across the initial state and the
relapsed state of the syndrome. We assume no distinction in characteristics between
the initial state and the relapsed state regardless of the syndrome category.
Data was accumulated from sources comprising differing cultures and levels of
advancement, different time periods, and different researchers operating independently.
Assuming the studies are not functionally equivalent and that the effect size may
differ in each study, we choose a random effects model for the analysis. The odds
ratio, computed as OR = ad
bc
(Table 2.1), is used as the effect size. The within study
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compute an estimate for the between-studies variance, τ 2, using the DerSimonian and
Laird method (Borenstein, Hedges, Higgins, and Rothstein, 2011). This estimate is
computed as





























, k is the
number of studies, and Wi is the weight of the ith study. The negative value of T 2
impies that the between-studies variability is 0. A Q-test for heterogeneity, formally
testing the hypothesis that all studies share a common effect size, also suggests that
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Table 2.1: Nomenclature of the 2 x 2 tables for nephrotic syndrome and atopy.
Nephrotic Non-Nephrotic Total
Atopic a b n1
Non-atopic c d n2
the between studies variability is negligible (Q=0.59, p=0.9643, Figure 2.2). Thus,
the random effects analysis is reduced to a fixed effects analysis.







, with the variance of the summary





(as the between studies variability is 0). The 95%
confidence interval for the summary effect, in log units, is given by M ± 1.96
√
VM .
We exponentiate the endpoints of this interval to convert to the odds ratio scale.
17
Figure 2.2: Forest plot and summary effect.
18
We performed all analyses using the open source software R (R Core Team, 2016).
Results were considered statistically significant for two-tailed p-values < 0.05.
2.3 Results
Five case control studies were selected from the 20 full text studies comprehensively
assessed. These studies were published between 1976 and 2007 with a total of 257
cases of pediatric nephrotic syndrome and 298 controls (studies 4, 10, 12, 21, and
22 in Appendix B). The included studies documented some form of atopic history
and included age-matched controls (Table 2.2). In each study, information on the
atopic history of the patients was obtained through parent questionnaires. Three
of the five studies in the analysis used hospital or clinic-based controls (Hilmanto,
2007; Yap et al., 1983; Thomson et al., 1976), one study used healthy children from
a nearby village (Meadow and Sarsfield, 1981), and one study did not indicate the
source population for the controls (Rebien et al., 1981). Meta-analysis of the five
case-control studies shows that a history of atopy in pediatric patients is significantly
associated with higher odds of idiopathic nephrotic syndrome (OR: 2.7; 95% CI: (1.77,
3.99); Figure 2.2). The odds of NS for atopic pediatric patients is 2.7 times higher
than the odds of NS for non-atopic pediatric patients.
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Table 2.2: Characteristics of included studies.
First Year Location Cases Controls Exposure Characteristics OR (95% CI) Diagnosis
Author Classification of Controls
Thomson 1976 London 40 40 History of asthma, Age-matched 2.83 (1.00,7.98) S.R.N.S.
eczema, or hayfever
Meadow 1981 Leeds 77 45 History of atopy Age, sex-matched 3.31 (1.24,8.84) MCD
S.R.N.S.
Rebien 1981 Heidelberg 42 30 History of atopy Similar age range 1.80 (0.43,7.62) MCD
(36/42)
Yap 1983 Singapore 59 100 History of atopy Similar age range 2.40 (1.18,4.89) Classical
S.R.N.S
Hilmanto 2007 Indonesia 39 83 History of atopy Similar age range 2.83 (1.29,6.20) FRNS
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2.4 Discussion
The implication of an association between some form of atopy and nephrotic syndrome
is well-documented (studies 4-23 in Appendix B). We used a meta-analysis to pool the
results from various studies to reach a more definitive conclusion on this association.
Our findings show that there is a significant association between atopy and odds of
nephrotic syndrome in pediatric patients.
Other findings of the studies used in the meta-analysis are noteworthy. The
Thomson study (1976) concluded that children with both Human Leukocyte Antigen
(HLA-2) and a history of atopy have a risk of S.R.N.S. that is thirteen times greater
than the risk for those with neither factor. The Rebien study (1981) concluded that
although IgE mediated hypersensitivity in children, measured by in vitro tests, may
coexist with nephrotic syndrome, it is not more prevalent than in a control population.
The study also suggests that a positive atopic history should be confirmed by skin
test or a radioallergosorbent test (RAST) before a subject is labeled as atopic (Rebien
et al., 1981). In two later studies (Meadow and Sarsfield, 1981; Yap et al., 1983), skin
tests, blood tests, RAST, and other forms of atopic identification were used contingent
upon parental consent, but those results were not investigated in our analysis. The
study by Meadow and Sarsfield (1981) found that some children with very high IgE
levels did not have an indication of history of an atopic disorder, and no significant
association existed between the frequency of certain HLAs and nephrotic syndrome.
In the Hilmanto study (2007), the author concluded that HLA Class II and atopy
together had an association with FRNS. These individual findings may be helpful in
the continued study of pediatric nephrotic syndrome and atopy.
Patterns of relapse of the nephrotic syndrome may be significantly associated with
atopy. One study reported that atopic children, particularly those suffering with
eczema, relapse sooner than non-atopic children (Trompeter, Barratt, Kay, Turner,
and Soothill, 1980). Another study reported that those treated at an older age
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relapsed less readily (Barratt, Osofsky, Bercowsky, Soothill, and Kay, 1975), but
the age effect is smaller when accounting for HLA-B12 and atopy (Trompeter et al.,
1980). Further studies which quantify atopy and the severity of allergic disease may
establish a predictive model for responsiveness to steroids as well as the nature of
relapse. The hyper-responsive immune function may be correlated with the risk of
relapse or time to initial remission, which would allow prospective stratification of
individuals with nephrotic syndrome. This prospective stratification could lead to
more precise treatment, which could reduce steroid toxicity and open up new domains
of therapeutics.
There are several limitations to this study. To begin with, differences in the
geographical locations of the studies may cause pediatric populations to vary widely.
The time differences in the studies are a source of bias due to advancements in medicine
and technology over the thirty-year period. In some studies, the relationship between
atopic activity and nephrotic syndrome was not a primary goal, which could contribute
to a form of selection bias. Particularly problematic is the assessment of the atopic
activity, which varied from study to study. Furthermore, having only five studies may
limit the accuracy or reliability of detecting true differences between studies (Hardy
and Thompson, 1998).
The significant association detected between atopy and pediatric nephrotic syn-
drome warrants further study. The study of the association between atopy and
pediatric nephrotic syndrome has been sporadic, and the term ‘atopy’ is not well-
defined; however, the results presented here can lead to new ideas and hypotheses that
encourage new, better defined and controlled studies. Case-control studies should be
initiated with well-defined atopic parameters to further study the association between
atopy and idiopathic nephrotic syndrome.
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Chapter 3
Pediatric Nephrotic Syndrome Data Description
3.1 South Carolina Data
In January 2016, data was retrieved for 436 pediatric patients with over 2000 visits
from the HSSC CDW database. Thirty-nine of the pediatric patients were diagnosed
with pediatric nephrotic syndrome, specifically, nephrotic syndrome with unspecified
pathological lesion in kidney (ICD 9 code 581.9). These diagnoses occurred between
July 2007 and August 2015. There were 19 females and 20 males with ages ranging
from 0-16 years at the time of diagnosis (Figure 3.1). The median age at diagnosis was
five years. There were ten African-Americans, two Asians, twenty Caucasians, three
Hispanic or Latino, and four classified as other or more than one race. Twenty-seven
were from a medium metropolitan area, 3 from a small metropolitan area, and 9 from
a non-metropolitan area. Twenty-seven of the patients were initially diagnosed in
the spring and summer months (March —August), while the remaining twelve were
diagnosed in the fall and winter months (September —February). Patients diagnosed
between 3 and 7 years of age accounted for over half of the diagnoses.
Fourteen of the patients identified retrospectively had accompanying lab data with
the date of diagnosis. One of the females is excluded from the analysis because of the
limited lab data available. The 8 females and 5 males are summarized in Table 3.1.
The lab data obtained are a part of a standard comprehensive metabolic panel
that can be routinely performed on patients. According to the U.S. National Library
of Medicine (2016), abnormal results can be due to a variety of medical conditions,
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Figure 3.1: Age distribution of SC pediatric nephrotic syndrome patients
at initial diagnosis.
Table 3.1: Summary lab data for 13 SC pediatric nephrotic syn-
drome patients.
Lab Mean (SD) Median Range UOM
Potassium Bld 5.42∗ (2.88) 4.6 4 - 14.7 mmol/L
Sodium Bld 138.38 (3.84) 138 133-145 mmol/L
CO2 Ser Pl 21.27 (6.89) 21 6 - 22 mmol/L
Anion 10.08 (5.11) 7 6 - 23 mmol/L
Chloride 107.92 (3.28) 107 103-113 mmol/L
BUN 31.92∗(40.09) 15 8 - 129 mg/dL
Calcium 8.12 (0.86) 8.1 5.8-9.3 mg/dL
Glucose 103.85∗(24.48) 94 75 - 156 mg/dL
Ser Albumin 1.78∗∗ (0.90) 1.6∗∗ 0.5 - 3.7 g/dL
* high based on normal range (U.S. National Library of Medicine,
2016)
** low based on normal range (U.S. National Library of Medicine,
2016)
including kidney failure. On average, patients in this study had elevated potassium
levels, which may be indicative of kidney disorders. Patients also had elevated blood
urea nitrogen (BUN) values, which could suggest the presence of kidney injury or
disease, and elevated glucose levels. Levels of albumin, one of the most abundant
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proteins in the body, were on average lower for the pediatric nephrotic syndrome
patient. Lower serum albumin levels are indicative of the nephrotic syndrome, where
the damaged kidney filtering system allows the protein to leak into the urine.
3.2 New Jersey Data
The medical records for children seen by the pediatric nephrologists at Robert Wood
Johnson Medical School before March 1997 and followed for at least one year were
reviewed by study authors (Constantinescu et al., 2000). There were nineteen females
and thirty-four males ranging in age from 1-13 years at the time of diagnosis (Figure
3.2). Twenty-five of the patients received a diagnosis of SDNS, nine were diagnosed
with FRNS, seventeen with infrequently relapsing nephrotic syndrome (IFRNS) and
two with SRNS. The median age at diagnosis was 3.5 years. The median number
of days to remission was 10, with remission defined by the study as protein-free
urine. The initial study reported a race distribution of 76.9% white, 8.9% black, 7.1%
Hispanic and 7.1% other.
Reported lab data included cholesterol level, creatinine level and the presence or
absence of hematuria. A summary of the lab data is presented in Table 3.2. Thirty of
the patients showed no hematuria at initial diagnosis, sixteen had micro-hematuria,
and seven exhibited macro-hematuria. The average cholesterol level for the group
was much higher than the upper bound of the normal range for cholesterol levels in
children and adolescents (American Academy of Pediatrics, 2015). High cholesterol
may result from a number of conditions, including kidney disease (Dietz and Stern,
2011).
3.3 Discussion
Pediatric nephrotic syndrome is classified as a part of the Rare Disease Clinical
Research Network (National Institute of Health, 2016). The pediatric nephrotic
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Figure 3.2: Age distribution of NJ pediatric nephrotic syndrome patients
at initial diagnosis.
Table 3.2: Summary lab data for NJ pediatric nephrotic
syndrome patients.
Lab Mean (SD) Median Range UOM
Cholesterol 424.16∗ (18.85) 387 201-799 mg/dL
Creatinine 0.49 (0.03) 0.5 0.1-1.0 mg/dL
* high based on normal range for children (American Academy
of Pediatrics, 2015)
syndrome data studied here are the result of retrospective chart reviews and are




distribution with application to negatively
skewed survival data
4.1 Introduction
The two-parameter gamma distribution has been used extensively in survival analysis.
It is useful for modeling survival processes that do not fit into a symmetric distribution
(X. Liu, 2012). Although flexibility is allowed by this unimodal two-parameter
distribution, the basic shape ranges from positively skewed for small values of the
shape parameter to approximately normal for large values of the shape parameter
for a fixed value of the scale parameter (Johnson, Kotz, and Balakrishnan, 2002;
Ofungwu, 2014). The Weibull, exponential, lognormal, and normal distributions
are alternative standard distributions commonly employed to model data that is
approximately normal to positively skewed (Hougaard, 1999).
The generalized gamma distribution is a three-parameter distribution that was
first presented by Stacy (1962) and includes as special sub-models the exponential,
Weibull, gamma and Rayleigh distributions. Variations of the generalized gamma
distribution have been proposed in recent years to enhance its modeling capability.
These include the Kumaraswamy generalized gamma distribution (de Pascoa, Ortega,
and Cordeiro, 2011), the exponentiated generalized gamma distribution (Cordeiro,
Ortega, and Silva, 2011), and the transmuted generalized gamma distribution (Lucena,
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Silva, and Cordeiro, 2015). These variations were designed to provide more flexibility
to the gamma distribution by allowing the capability of modeling both monotone and
non-monotone failure rates (Lucena et al., 2015). Despite the improved flexibility, the
distributions are generalizations of the standard two-parameter gamma distribution
and are still mainly utilized for positively skewed data.
The Gompertz distribution is a standard distribution for modeling negatively
skewed survival data. It was originally developed in 1825 to model human mortality
(Gompertz, 1825). A major drawback of the Gompertz distribution is that it fits
only adult mortality sufficiently (Thatcher, 1999). Several variations or extensions of
the Gompertz distribution have also been introduced in response to the modeling of
human mortality data (Cooray and Ananda, 2010).
Aside from the Gompertz distribution and its extensions, variations of the normal
distribution have been proposed to model negatively skewed data. These include the
skew normal (Azzalini, 1985), the power normal (Gupta and Gupta, 2008), the tilted
normal (Maiti and Dey, 2012), and a generalized normal distribution (Robertson
and Allison, 2012). Nevertheless, the applicability of these distributions is limited.
Practical difficulties of estimating the skewness parameter for small to moderate
sample sizes have been noted with the skew normal distribution, as well as problems
with goodness of fit for the power normal distribution (Maiti and Dey, 2012). The
tilted normal distribution is derived using a Marshall-Olkin transformation to induce
skewness; however, this transformation applied to a unimodal symmetric density
results in a distribution that is not flexible enough to handle data presenting high or
moderate skewness (Rubio and Steel, 2012). The generalized normal distribution was
constructed to model human longevity and distributional properties involve constraints
relevant only to life table data (Robertson and Allison, 2012).
We propose a reflected, shifted, truncated version of the two-parameter gamma
distribution as an alternative distribution for modeling negatively skewed survival data
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and demonstrate the applicability of this distribution using three types of survival
data: complete, where the event of interest is observed exactly; right-censored, where
the event of interest is only known to have not occurred by a given time point; and
interval-censored, where the event of interest is only known to have occurred in a
particular interval of time.
4.2 The Reflected-Shifted-Truncated-Gamma Distribution
The reflected-shifted-truncated-gamma (RSTG) distribution is constructed through a
series of transformations to the two-parameter gamma distribution. The probability
density function of the two-parameter gamma distribution is
f(t|α, θ) = 1Γ(α)θα e
− t
θ tα−1, 0 < t <∞.
Here, α > 0 represents the shape parameter and θ > 0 represents the scale parameter.
Reflecting the two-parameter gamma distribution about the y-axis and shifting it
k > 0 units to the right gives a probability density function of




θ (−t+ k)α−1,−∞ < t < k;α, θ > 0.
The cumulative distribution function of this three-parameter reflected, shifted gamma
distribution is















for t < k where Γ(a) =
∞∫
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represents the upper incomplete gamma function.
Truncating the reflected, shifted gamma distribution at 0 effectively restricts the
new distribution to the interval [0, k). The probability density function for this RSTG
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distribution is















)e− (−t+k)θ (−t+ k)α−1 α > 0, θ > 0, 0 ≤ t < k,
(4.1)
with cumulative distribution function given by



























Complete derivations of the density and distribution functions are given in Appendix
C.
Plots of the probability density function for values of α, θ and k are given in Figure
4.1.

























α = 0.5,θ = 2
α = 2,θ = 2
α = 4,θ = 2
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α = 3,θ = 0.5
α = 3,θ = 2
α = 3,θ = 4
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Figure 4.1: Probability density function of the RSTG distribution with varying α, θ;
k=90.
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4.2.1 Quantile Function and Moments of the RSTG Distribution
The quantile function of the RSTG distribution is defined as Q(p) = inf{t : F ∗(t) ≥ p}






















For a given p ∈ (0, 1], tp = Q(p) represents the 100pth percentile.
The quantile function of the distribution can be used to construct quantile analogs of
standard moment-based descriptive measures and to extend those standard descriptive
measures (Gilchrist, 2000). We can use this function to generate random data that
describe the density given in Equation (4.1).
The nth raw moment of the RSTG distribution is given by
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In particular, the first moment is
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where α > 0, θ > 0, and k > 0. Hence, the mean of the RSTG distribution is
E(T ) = k −
θ
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4]− 4µE[T 3] + 6µ2E[T 2]− 3µ4
σ4
where µ = E[T ]. Plots of the mean, variance, skewness, and kurtosis functions of the
RSTG distribution with α = 1 and k = 96 are shown in Figure 4.2.
4.2.2 Survival and Hazard Functions of the RSTG Distribution
The survival and hazard functions of the RSTG distribution are
























)) , for α > 0, θ > 0, 0 < t < k (4.4)
respectively. Plots of the survival and hazard functions for values of α and θ for a
fixed k are shown in Figure 4.3.
4.3 Parametric Estimation
Both frequentist and Bayesian approaches can be used to estimate the parameters of a
survival model (Pradhan and Kundu, 2011). Typically, parametric estimation follows
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Figure 4.2: The mean, variance, skewness and kurtosis of the RSTG distribution
with α = 1 and k = 90.
the frequentist approach and is based on likelihood methods (Lee and Wang, 2003;
Kalbfleisch and Prentice, 2011). Parametric estimation for the RSTG distribution
will use the method of maximizing the log-likelihood function.
4.3.1 Maximum Likelihood Estimation for Complete Data
Let t1, t2, ..., tn be a random sample of size n with probability density function given
by equation (4.1). The likelihood function for the parameter vector Θ = (α, θ, k)
based on the observed sample is proportional to
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Figure 4.3: Survival function and hazard function of the RSTG distribution with





































ln (−ti + k) .
(4.5)
We assume that the parameters α, θ and k are unknown. We obtain the normal
equations for the unknown parameters by taking partial derivatives of equation (4.5)
with respect to α, θ and k and equating each to zero. The resulting equations, in



















ln (−ti + k) = 0, (4.6)
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The solutions of equations (4.6), (4.7) and (4.8) are candidates for the maximum
likelihood estimates (MLEs) of the parameters α, θ and k. The maximum is attained
at the candidate values α̂, θ̂, and k̂ if the Hessian matrix (Appendix D) is negative
definite at those candidate values.
Although the MLEs of the unknown parameters can be obtained, we cannot obtain
the exact distribution of the MLEs. We use the large sample approximation. Assuming
regularity conditions are satisfied, the asymptotic confidence intervals can be obtained
by using the observed Fisher information matrix.
For parameter vector Θ = (α, θ, k), the observed Fisher information matrix is
given by
I (Θ) = −

H11 (Θ) H12 (Θ) H13 (Θ)
H21 (Θ) H22 (Θ) H23 (Θ)







where Hij (Θ) represents the ijth entry of the Hessian matrix (Appendix D). The
variance-covariance matrix of the parameter estimates can be approximated by the
inverse of the information matrix











where K = a(df − e2)− b(bf − ec) + c(be− cd) and ()∗ represents the adjoint of the














We can use equation (4.9) to derive approximate 100(1− τ)% confidence intervals



















where zτ/2 is the upper 100(τ/2)th percentile of the standard normal distribution.
The MLEs cannot be solved for explicitly here and must be found by numeric
methods such as Newton-Raphson’s algorithm. Details of the Newton-Raphson
algorithm and other numeric methods can be found in textbooks on numerical methods
for optimization, such as Iterative Methods for Optimization by Carl Kelley (1999).
We use iterative methods in R to obtain the MLEs and standard errors.
4.3.2 Maximum Likelihood Estimation for Right-Censored Data
Let t1, t2, ..., tn be a right-censored random sample of size n with probability density
function given by equation (4.1). The censoring indicator δi is such that
δi =

1 if the event of interest is observed
0 if the event of interest is not observed (event time is right-censored)
.
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We calculate partial derivatives of equation (4.11) with respect to α, θ and k to
obtain the normal equations for the unknown parameters and equate each to zero.










































with Γ′(α), and Γ′(α, k
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We obtain the MLEs, standard errors and confidence intervals using methods
discussed in Section 4.3.1.
4.3.3 Maximum Likelihood Estimation for Interval-Censored Data
Let t1, t2, ..., tn be a random sample such that ti ∈ [li, ri), li ≤ ri, where li is the left
limit of the ith censored data point and ri is the right limit of the ith censored data





















































To obtain the normal equations for the unknown parameters, we calculate partial





































with Γ′(α), and Γ′(α, k
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We again obtain the MLEs, standard errors and confidence intervals using methods
discussed in Section 4.3.1.
4.4 Simulations
A series of Monte Carlo simulations are conducted to assess the performance and
consistency of the maximum likelihood estimators for the RSTG distribution. Bias
and mean squared error (MSE) criteria are used for comparison purposes. For each of
1000 samples, we generate n = 20, 40, 60, 80, 100 and 200 random variables Ti, i = 1...n,
from the RSTG distribution with shape parameter α = 2, scale parameter θ = 2, and
shift parameter k = 96 using equation (4.2).
To generate right-censored data values, administrative censoring is used following a
method by Michael and Lambert (Crowther and Lambert, 2013) so that the censoring
percentage is approximately 10−20%. To generate interval-censored data, we generate
n values from the RSTG distribution to serve as left endpoints of each interval. We
sort the values and use a pre-specified probability from the uniform distribution to
determine which of the two adjacent ordered values will serve as the right endpoint.
We fit each complete, right-censored, and interval-censored sample using the RSTG
distribution.
The mean values of the parameter estimates, bias, and MSE for each sample
size are presented in Table 4.1. Standard errors were calculated using the bootstrap
method.
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Table 4.1: Estimated standard error, bias and MSE of MLE of parameters based on 1000 simulations of complete, right-censored
and interval-censored data of the RSTG(2,2,96) distribution with n=20, 40, 60, 80, 100, and 200.
Complete Right-censored Interval-censored
n MLE (se) Bias MSE MLE (se) Bias MSE MLE (se) Bias MSE
20 α 1.63 (1.59) -0.37 2.653 3.41 (1.74) 1.41 4.990 3.78 (2.44) 1.78 9.118
θ 2.94 (1.23) 0.94 2.410 2.20 (1.16) 0.20 1.387 1.61 (0.81) -0.39 0.808
k 95.65 (0.62) -0.35 0.504 96.63 (1.15) 0.63 1.729 95.62 (0.65) -0.38 0.560
40 α 1.87 (1.49) -0.13 2.233 3.04 (1.73) 1.03 4.990 2.99 (2.14) 0.99 5.562
θ 2.49 (1.28) 0.49 1.881 1.94 (0.82) -0.07 0.679 1.77 (0.74) -0.23 0.607
k 95.85 (0.59) - 0.15 0.372 96.49 (0.95) 0.49 1.145 95.67 (0.62) -0.33 0.488
60 α 1.89 (0.93) -0.11 0.885 2.66 (1.63) 0.66 3.109 2.65 (1.90) 0.65 4.040
θ 2.29 (1.07) 0.29 1.230 1.94 (0.69) -0.06 0.478 1.88 (0.62) -0.12 0.395
k 95.87 (0.35) -0.13 0.142 96.31 (0.98) 0.31 1.065 95.72 (0.47) -0.28 0.295
80 α 1.91 (0.53) -0.09 0.291 2.55 (1.21) 0.55 1.769 2.49 (1.49) 0.49 2.46
θ 2.18 (0.85) 0.18 0.747 1.95 (0.65) -0.05 0.431 1.92 (0.61) -0.08 0.374
k 95.90 (0.24) -0.10 0.066 96.28 (0.94) 0.28 0.968 95.74 (0.48) -0.26 0.298
100 α 1.90 (0.53) -0.10 0.286 2.48 (1.16) 0.48 1.578 2.44 (0.25) 0.44 0.255
θ 2.14 (0.60) 0.14 0.375 1.95 (0.55) -0.05 0.307 1.92 (0.38) -0.08 0.152
k 95.90 (0.21) -0.10 0.052 96.26 (0.74) 0.26 0.623 95.79 (0.005) -0.21 0.045
200 α 1.93 (0.28) -0.07 0.085 2.18 (0.64) 0.18 0.444 2.40 (0.16) 0.40 0.189
θ 2.08 (0.33) 0.08 0.115 1.98 (0.31) -0.02 0.099 1.94 (0.19) -0.06 0.039
k 95.93 (0.15) -0.07 0.027 96.10 (0.42) 0.10 0.190 95.85 (0.004) -0.15 0.021
40
As the sample size increases for all three censoring scenarios, the bias and mean
squared error decreases, verifying the consistency of the estimators (Table 4.1).
4.5 Applications
In this section, we present three real data sets to demonstrate the flexibility and
potential of the RSTG distribution in modeling negatively skewed data. We compare
the performance of the RSTG distribution to the exponential, generalized F, generalized
gamma, Gompertz, log-logistic, lognormal, Rayleigh andWeibull distributions. Density
functions of the compared distributions are given in Appendix E. We use four
discrimination criteria methods based on the log-likelihood function evaluated at
the MLEs. Letting p be the number of parameters to be fitted, n the sample size,
and l(α̂, θ̂, k̂) the log-likelihood function, the criteria we consider are the following:
Akaike information criteria AIC = −2l(α̂, θ̂,k̂) + 2p, corrected Akaike information
criterion AICC = AIC + 2p(p+1)(n−p−1) , Hannan-Quinn information criterion HQIC =
−2l(α̂, θ̂, k̂) + 2p log(log(n)), and the consistent Akaike information criterion CAIC =
−2l(α̂, θ̂, k̂) + p(log(n) + 1) (Anderson, Burnham, and White, 1998; Hannan and
Quinn, 1979). An advantage in using information-theoretic criteria is that it is valid
even for non-nested models (Burnham and Anderson, 2002). Burnham and Anderson
suggest that an AIC difference of between 3 and 7 units indicates that a candidate
model has considerably less support than the model with the minimum AIC value,
while a difference of more than 10 units indicates that a candidate model is highly
unlikely.
4.5.1 Badenscallie Burial Data
In this first example, ages of death for 59 males members of the Scottish McAlpha
clan were collected in June 1987 from the burial ground at Badenscallie in the Coigach
district of Wester Ross, Scotland (Sprent and Smeeton, 2007). The ages are recorded
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Figure 4.4: Data distribution and survival functions of the four best models of the
Badenscallie data.
in complete years, e.g. 0 means before the first birthday and 75 means after the 75th
but before the 76th birthday. The negative skew of this distribution is verified by the
skewness coefficient of −0.79. The distribution of death times is shown in Figure 4.4.
We compare the performance of the RSTG distribution with the aforementioned
distributions. Information theoretic criteria, parameter estimates and standard errors
for each of the fitted distributions are given in Table 4.2. A graphical summary of
four model fits, relative to the Kaplan-Meier survival curve, is shown in Figure 4.4.
Based on the AIC, AICC, HQIC and CAIC values, the RSTG distribution provides
a better fit than all other distributions. The RSTG distribution has an AIC value
that is more than 10 units lower than the other distributions in Table 4.2 and is thus
superior to the compared distributions for modeling negatively skewed complete data.
4.5.2 Diabetic Data
In this second example, survival times were collected for the first 40 diabetic patients
enrolled in an Oklahoma Indian diabetes study (Cooray, 2005). This data is a part
of a larger sample of 1012 Oklahoma Indians with non-insulin-dependent diabetes
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Table 4.2: Model fitting results of the Badenscallie data.
Model Par MLE (se) AIC AICC HQIC CAIC
Exponential λ 0.016 (0.002) 606.69 606.76 607.50 609.77




Generalized µ 4.550 (0.044) 541.69 542.13 544.12 550.92
Gamma σ 0.133 (0.026)
Q 28.3 (161)
Gompertz a 0.050 (0.007) 539.68 539.89 541.30 545.84
b 0.001 (0.0006)
Log-logistic α 0.542 (0.121) 625.34 625.55 626.96 631.50
β 57.74 (0.113)
Lognormal µ 3.730 (0.188) 655.37 655.58 656.99 661.53
σ 1.450 (0.133))
Rayleigh b 4.210 (0.065) 592.49 592.56 593.30 595.57
Weibull λ 1.709 (0.208) 592.49 592.56 593.30 595.57
γ 66.331 (5.146)
RSTG α 1.083 (0.392) 526.83 527.27 529.26 536.06
θ 42.709 (28.261)
k 95.065 (0.409)
mellitus who were examined in 1972 –1980 and had a follow-up study conducted
in 1986–1989 (Lee and Wang, 2003). Some of the survival times are right-censored.
The skewness coefficient of −1.30 verifies the negative skew of the distribution. The
distribution of survival times is shown in Figure 4.5.
We compare the performance of the RSTG distribution with the aforementioned
distributions. Information theoretic criteria, parameter estimates and standard errors
for each of the fitted distributions are given in Table 4.3. A graphical summary of
four model fits, relative to the Kaplan-Meier survival curve, is presented in Figure 4.5.
The RSTG distribution has an AIC value that is more than 10 units lower than the
other distributions and is thus superior to the compared distributions for modeling
negatively skewed right-censored data.
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Figure 4.5: Data distribution and survival functions of the four best models of the
diabetic data.
4.5.3 Breast Retraction Data
In a final example, times to breast retraction were collected from a retrospective study
on 46 early breast cancer patients treated with radiation therapy at the Joint Center
for Radiation Therapy in Boston between 1976 and 1980 (Finkelstein and Wolfe,
1985). The breast retraction times are interval-censored. We use the midpoints of
each interval-censored observation to calculate a skewness coefficient of −0.71, which
verifies the negative skew of the distribution.
The parameter estimates and corresponding standard errors, and the information
theoretic criteria for the RSTG, exponential, generalized F, generalized gamma,
Gompertz, log-logistic, lognormal, Rayleigh and Weibull distributions are given in
Table 4.4. A graphical summary of the RSTG model and the four best models based
on the AIC values, relative to the Kaplan Meier survival curve, is shown in Figure 4.6.
Based on the information theoretic criteria, the RSTG distribution provides a better
fit than the compared distributions.
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Table 4.3: Model fitting results of the diabetic data.
Model Par MLE(se) AIC AICC HQIC CAIC
Exponential λ 0.089 (0.014) 275.56 275.59 276.78 279.56




Generalized µ 2.73 (0.023) 213.00 213.17 216.66 225.01
Gamma σ 0.025 (0.073)
Q 21.7 (62.9)
Gompertz a 0.396 (0.060) 210.18 210.26 212.62 218.19
b 0.002 (0.002)
Log-logistic α 2.767 (0.395) 269.39 269.47 271.83 277.40
β 1.056 (1.014)
Lognormal µ 2.191 (0.186) 305.83 305.91 308.27 313.84
σ 0.886 (0.056)
Rayleigh b 2.48 (0.079) 247.93 247.96 249.15 251.93
Weibull λ 2.561 (0.375) 247.32 247.40 249.76 255.33
γ 12.177 (0.766)




The flexibility, applicability and better fit of the RSTG distribution as compared
to eight standard distributions has been demonstrated when modeling negatively
skewed complete, right-censored and interval-censored survival data by AIC, AICC,
HQIC, and CAIC criteria. The data sets used in Examples 4.5.1 and 4.5.2 were
previously modeled with extensions of the Gompertz distribution. The Gompertz-sinh
family was constructed to model highly negatively skewed survival data with thick
lower tails, such as the Badenscallie data used in Example 4.5.1. This data set was
analyzed using the Gompertz-sinh and the exponentiated Gompertz-sinh distributions.
(Cooray and Ananda, 2010). A logistic-sinh distribution, designed for negatively
skewed distributions with long thin tails, has been proposed to model the subset












































Figure 4.6: Data distribution and survival functions of the four best models of the
breast retraction data.
the compared standard distributions, the RSTG distribution is comparable to the
Gompertz-sinh family for negatively skewed survival data with thick tails and performs
better than the Gompertz-sinh family and the logistic-sinh distribution when modeling
negatively skewed distributions with thin tails. The RSTG distribution is a viable
alternative when researchers encounter negatively skewed survival data.
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Table 4.4: Model fitting results of the breast retraction data.
Model Par MLE(se) AIC AICC HQIC CAIC
Exponential λ 0.032(0.005) 215.02 215.11 215.73 217.89




Generalized µ 3.860(0.022) 162.44 162.99 164.56 171.05
Gamma σ 0.077(0.031)
Q 7.777(2.940)
Gompertz a 0.077(0.047) 176.58 176.85 177.99 182.32
b 0.004(0.002)
Log-logistic α 2.54(0.115) 209.58 209.85 210.99 215.32
β 29.21(9.219)
Lognormal µ 3.258(0.107) 210.97 211.24 212.38 216.71
σ 0.706(0.081)
Rayleigh b 3.55(0.075) 190.52 190.61 191.23 193.39
Weibull λ 2.17(0.30) 192.17 192.44 193.58 197.91
γ 35.33(0.35)





An Accelerated Failure Time Model Using the
RSTG Distribution with Application to
Pediatric Nephrotic Syndrome
5.1 Introduction
The classical accelerated failure time (AFT) model (Kalbfleisch and Prentice, 2011)
provides an attractive alternative to the Cox proportional hazards model (D. R. Cox,
1972) in survival analysis due to its direct physical interpretation. We can express
the survival time of one patient as being accelerated or decelerated by some factor as
compared to another patient while taking into account covariates that contribute to
the change in survival time. Accelerated failure time models allow for a wide range
of parametric forms for the survival functions. A fully parametric model has the
advantage of a simple framework for maximum likelihood estimation. The parameter
estimates then have desirable properties such as asymptotic normality. The suitability
of the parametric distribution to the data can easily be assessed using graphical
methods, and inference will be far more precise (Collett, 2015).
In Chapter 4, we demonstrated that the RSTG distribution provides a better
model fit for negatively skewed complete, right-censored and interval-censored survival
data than the exponential, generalized gamma, generalized F, lognormal, log-logistic,
Rayleigh, Gompertz and Weibull distributions. In this chapter, we use the RSTG
distribution in an accelerated failure time model and apply it to the pediatric nephrotic
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syndrome data. The AFT model is our model of choice as we expect that some of
the explanatory variables suggested by the literature will actually decelerate the time
to remission for the frequently relapsing or steroid dependent nephrotic syndrome
patient.
5.2 The Model
The accelerated failure time model has a log-linear representation as
log Ti = β0 + β1x1i + β2x2i + .. . . .+ βpxpi + σεi, (5.1)
where Ti is the random variable associated with the survival time of the ith
individual, β0 is the true intercept term, β1, . . . , βp are the regression coefficients of
interest, xji is the jth explanatory variable (covariate) for the ith individual (i =
1, 2, . . . , n; j = 1, 2, . . . , p), σ is a scalar, and εi is a random disturbance term assumed
to be identically and independently distributed with density function f(εi).
The regression coefficients of the model in equation (5.1) are interpreted as follows:
If we increase the value of xki by 1 and hold all other covariates fixed, the change in
survival time will increase (if βk > 0) or decrease (if βk < 0) by a factor of eβk . In
other words, 100eβk represents the percentage change in median survival time.
Following the log-linear model formulation in equation (5.1), we express time T as
T = exT β+σε = exT β(eεσ) = exT β(T0).
We assume that T0 = eσε follows the RSTG distribution, with density function
(4.1), survival function (4.3), and hazard function (4.4).
49
Given Θ = (α, θ,β, k), we write the survival function for the RSTG AFT model as
SA(t|x,Θ) = P (T ≥ t) = P (ex
T β(T0) ≥ t)
= P (T0 ≥ e−x
T βt)










)e− (−x+k)θ (−x+ k)α−1dx







) , where g(t) = e
−xT βt.
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S∗ (g(t))
= h∗ (g(t)) · g′(t)
= e
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where g′(t) = e−xT β.




Several approaches have been proposed for the estimation and inference of the semi-
parametric AFT model. One method involves rank-based estimators as first discussed
in the literature by Prentice (1978), and another is the method of Buckley and
James (1979), which provides an accommodation of the least-squares estimator. The
asymptotic properties of the two estimators have been studied by many authors
(Tsiatis, 1990; Ritov, 1990; Jin, Lin, Wei, and Ying, 2003). Classically, the estimation
of the parameters in a fully parametric AFT model is performed by maximizing the
log-likelihood equation (David Roxbee Cox and Oakes, 1984; Robins, 1992). We will
use maximum likelihood methods for estimation of the parameters of the RSTG AFT
model.
For data that contains both complete and right-censored information, the likelihood





























where g(t) = e−xT βt. The censoring indicator δi is such that
δi =

1 if the event of interest is observed
0 if the event of interest is not observed (event time is right-censored)
.
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We take partial derivatives of equation (5.3) with respect to α, θ, k, and each βj
to obtain the normal equations for the unknown parameters and equate each to zero.
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−e−xT βti + k
)) (
−e−xT βti + k
)} = 0.
(5.7)
Techniques discussed in Section 4.3.1 can be applied to equations (5.4), (5.5), (5.6),
and (5.7) to find the MLEs. These equations cannot be solved explicitly. We use
iterative methods in R to obtain the MLEs and standard errors.
5.4 Application to Pediatric Nephrotic Syndrome
An illustration of the superior performance of the proposed RSTG AFT regression
model (5.1) compared to AFT regression models with other distributional assumptions
is given in Appendix F. The comparisons are based on information theoretic criteria
and standard errors of the parameter estimates. We now apply the RSTG AFT model
to the pediatric nephrotic syndrome data from HSSC and from the Robert Wood
Johnson Medical School.
5.4.1 HSSC Data
To demonstrate the applicability of the RSTG distribution to real negatively skewed
data, we first analyze pediatric nephrotic syndrome data from the HSSC CDW
described in Chapter 3.
Hospital readmission, particularly in the pediatric population, has been the focus of
previous studies (Feudtner et al., 2009; Gay, Hain, Grantham, and Saville, 2011). The
times to the first hospital visit within the first 30 days after diagnosis of pediatric NS
were recorded from a retrospective analysis of the HSSC data. We choose 30 days as a
censoring point to account for possible scheduled return visits, and because previous
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literature suggests that only a small percentage of pediatric nephrotic syndrome
patients have not entered remission after 4 weeks (Constantinescu et al., 2000).
Previous literature also suggests that the time to remission for the frequently relapsing
or steroid dependent nephrotic syndrome patient is longer than that of the infrequently
relapsing patient (Constantinescu et al., 2000; Nakanishi et al., 2013). According to
one American study, 52% of IFRNS patients achieved initial remission by 7 days after
diagnosis, while only 21% of the FRNS and SDNS patients achieved initial remission by
7 days (χ2 = 4.5; p = 0.03) (Constantinescu et al., 2000). We hypothesize that those
whose time to initial remission is longer, i.e. the FRNS or SDNS patient, are more
likely to have a return hospital visit within a 30-day period. This return visit could be
prompted by complications arising from the body being in the state of the nephrotic
syndrome, such as severe edema, hypertension, or bacterial peritonitis (Richardson,
2012; Debbie S. Gipson et al., 2009). The return visit could also occur because of
adverse events resulting from the prolonged use of high dosage corticosteroid therapy
which is classically used for the initial diagnosis of idiopathic pediatric nephrotic
syndrome.
We use the continuous covariate age and categorical 0/1 covariates representing the
season of diagnosis (with spring being the referent level) to identify predictive factors
for the time to the first hospital visit after diagnosis of the nephrotic syndrome. We
define season of diagnosis as: fall (August, September, October); winter (November,
December, January); spring (February, March, April) and summer (May, June, July).
The distribution of times to first hospital visit after diagnosis has skewness coefficient
−0.88 (Figure 5.1).
The AFT model for this data is given by
log(Ti) = β0 + β1agei + β2winteri + β3summeri + β4falli + σεi. (5.8)
where Ti represents the time to first hospital visit for the ith patient, i = 1, .., n.
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Figure 5.1: Distribution of times to first hos-
pital visit after initial diagnosis of pediatric
nephrotic syndrome from HSSC CDW.
We analyze the data under the accelerated failure time framework with different
distributional assumptions. Results are presented in Appendix F.
To assess the suitability of a model, graphical checks may be preferred over formal
statistical tests of lack of fit because the formal tests tend to have low power for
small-sample sizes or they always reject a given model for large sample sizes (Klein
and Moeschberger, 2003). Cox-Snell residuals, Martingale residuals and deviance
residuals are three types of residuals that are commonly used to assess the fit of a
model graphically (see John P. Klein and Moeschberger (2003) and Collett (2015)
for a discussion of each). We evaluate the accuracy of the RSTG AFT model using
a diagnostic plot of the deviance residuals. The deviance residuals, first introduced
by Terry M. Therneau, Grambsch, and Fleming (1990), can be expected to be
symmetrically distributed about zero when an appropriate model has been fit. The
deviance residuals are defined as rDi = sgn(Mi)[−2{Mi + δi log(δi −Mi)}]
1
2 , where δi
is the censoring indicator, Mi = δi + log ŜA(ti) , and sgn(·) is a function that simply
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Figure 5.2: Deviance residual plots of the RSTG AFT model for the HSSC CDW
pediatric nephrotic syndrome data.
Table 5.1: RSTG AFT model for pediatric
nephrotic syndrome patients in South Car-
olina.
Distribution Parameter MLE(se)




takes the sign of the argument. A plot of the deviance residuals indicates that the
RSTG AFT model provides a good fit for the data (Figure 5.2).
No significant predictors of the time to first hospital visit after diagnosis were
detected by the RSTG AFT model (Table 5.1).
5.4.2 Robert Wood Johnson Medical School Data
As a second example demonstrating the applicability of the RSTG distribution to
negatively skewed data, we use the New Jersey data described in Chapter 3. Previous
analyses of the New Jersey data reported a median time to initial remission of 7 days
for IFRNS patients and a median time to initial remission of more than 7 days for
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the FRNS and SDNS patients (Constantinescu et al., 2000). These median remission
times coincide with those of a later study by Vivarelli et al. (2010). The original study
of this data analyzed odds ratios between the IFRNS group and the FRNS/SDNS
group. Each group was assessed for time to first remission with censoring after 7
days (Constantinescu et al., 2000). A significant association was found between initial
remission times less than 7 days and an IFR diagnosis for those patients who did not
have hematuria at diagnosis. Study authors also report that they did not take into
account the histopathology found on renal biopsy.
The objective of our study of the New Jersey data is to identify early prognostic
factors for idiopathic nephrotic syndrome, particularly FRNS or SDNS. We use the
RSTG AFT model to examine predictors of the time to first remission for pediatric
nephrotic syndrome patients. The variables age at diagnosis, hematuria (0 = not
present at diagnosis, 1 = present at diagnosis), and creatinine level (mg/dL) are used
to determine their effects on the accelerated or decelerated time to initial remission.
All patients were initially treated with the standard corticosteroid therapy. Following
the ideas of the original study authors, we fit the model using censoring at 7 days
after diagnosis. Censoring at 7 days results in a negatively skewed distribution of
initial remission times with skewness coefficient −2.68.
The AFT model for this data is given by
log(Ti) = β0 + β1agei + β2hematuriai + β3creatininei + σεi, (5.9)
where Ti represents the time to first remission for the ith patient, i = 1, .., n. Censoring
at 7 days for the RSTG AFT model did not detect significance of any predictors of
the time to first remission (β1 = −0.012, SE = 0.026; β2 = −0.330, SE = 0.201; β3 =
0.102, SE = 0.562). We explore later censoring times to determine if any significant
effects are present.
Further review of the New Jersey data reveals that the mean time to first remission
for FRNS and SDNS patients is 10 days and the median time is 11.5 days. Study
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Figure 5.3: Deviance residual plots of the RSTG AFT model for the New Jersey
pediatric nephrotic syndrome data.
findings also indicate that 75% of IFRNS patients are in remission at 14 days. Because
the objective is to identify as early as possible significant predictors of NS patients
who tend toward a FR or SD course, we use the study the data for up to 14 days
after diagnosis. This is consistent with a startup study with follow-up time of 14 days.
This convention results in a negatively skewed distribution of initial remission times
with skewness coefficient −0.40. We apply the RSTG AFT model to the data. A
plot of the deviance residuals indicates the presence of outliers that may affect model
fit (Figure 5.3). One outlier corresponds to an individual who entered spontaneous
remission while the other corresponds to an individual with a very low creatinine level
at diagnosis. The model was refit without the outliers and neither the magnitude nor
significance of the parameter estimates changed substantially. Original model fitting
results are given in Table 5.2.
Based on the parameter estimates and standard errors, the model suggests that age
at diagnosis is a significant indicator of the time to first remission (β1 = −0.172, SE =
0.052). After controlling for hematuria status and creatinine level, the time to first
remission for pediatric NS patients decreases by 16%(95% CI : 7%−24%) for each one
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Table 5.2: RSTG AFT model for pediatric
nephrotic syndrome patients in New Jersey.
Distribution Parameter MLE(se)
RSTG β1 -0.172 (0.052)
β2 0.396 (0.592)
β3 5.158 (3.245)
year increase in age at diagnosis. This finding supports the findings of R. F. Andersen
et al. (2010), who suggested that early age at debut in a significant predictor of SDNS
and FRNS.
5.5 Discussion
Potential two-way interactive effects were explored in the Robert Wood Johnson
medical school data. No interactions were found to be significant.
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Chapter 6
Frailty Models using the RSTG Distribution
with Application to Pediatric Nephrotic
Syndrome and Diabetic Retinopathy
6.1 Introduction
In practice, there can exist either unobserved or unmeasurable effects that cause an
individual or group of individuals to experience an event sooner or later than expected.
These non-measured random effects, commonly referred to as frailties, may evoke
significant changes in survival probabilities if accounted for in the modeling process.
The concept of frailty was introduced as early as 1979 in a discussion of the impact of
heterogeneity of individual frailty on the dynamics of mortality (Vaupel, Manton, and
Stallard, 1979). The underlying logic of frailty models is that some subjects (or groups
or clusters) are intrinsically more or less prone to experience an event of interest than
are others, and that the distribution of these effects can be at least approximated
(Box-Steffensmeier and De Boef, 2006).
Frailty models in survival analysis are commonly used to quantify the association
between individual survival times within a subgroup (John P. Klein and Moeschberger,
2003). For example, there may be a shared genetic structure or a shared environmental
factor that leads to dependence among the event times. This shared frailty concept
was first introduced by Clayton (1978) and has been studied more extensively by many
researchers, most within the framework of the PH model (Oakes, 1989; McGilchrist
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and Aisbett, 1991; Hougaard, 1986b; John P Klein, Moeschberger, Li, Wang, and
Flournoy, 1992; Keiding, Andersen, and Klein, 1997; John P. Klein and Moeschberger,
2003; Terry M Therneau, Grambsch, and Pankratz, 2003; Chen et al., 2013). While
the shared frailty model accounts for unobserved covariates that operate at categorized
levels above the individual unit, the individual frailty model accounts for heterogeneity
among individual units (Gutierrez et al., 2002). The individual frailty model can
be used to model the effect of important covariates that have not been observed
(Wienke, 2010). The correlated frailty model, in which the frailties of individuals in a
cluster are correlated but not necessarily shared, is a natural extension of both the
individual and the shared frailty model concept (Wienke, 2010). Correlated frailty
models have been used in multiple studies, including studies of diabetic retinopathy
(Huster, Brookmeyer, and Self, 1989), studies of acquisition of both Hepatitis A and
Hepatitis B (Hens, Wienke, Aerts, and Molenberghs, 2009), and studies of kidney
infection (Hanagal, Pandey, and Ganguly, 2015). Frailty models can also be used
to model event dependence arising from repeated occurrence of the same type of
event within an individual. Examples include recurrent hospitalizations for transplant
candidates with kidney disease, pulmonary exacerbations in cystic fibrosis asthma
attacks, or relapse of diseases (Greenwood and Yule, 1920; Box-Steffensmeier and
De Boef, 2006; L. Liu, Wolfe, and Huang, 2004; Oakes, 1992).
The choice of frailty distribution plays an important role in the survival model.
Theoretically, any non-negative distribution can be used as a frailty distribution. The
most commonly used distributions are the gamma and the lognormal, but others
include the inverse Gaussian, inverse gamma and the positive stable distribution
(Aalen, 1994; P. K. Andersen, Klein, Knudsen, and y Palacios, 1997; Balakrishnan and
Peng, 2006; Duchateau and Janssen, 2007; Wienke, 2010; Hougaard, 1986, 2012). The
choice of the frailty distribution is often driven by mathematical convenience (Chen et
al., 2013). The effects of different frailty distributions have been investigated by several
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authors, including Pickles and Crouchley (1995) and Hanagal and Sharma (2015).
The use of gamma distributed frailty in univariate survival models is supported by the
results of Abbring and Van Den Berg (2007), who showed that, under some regularity
assumptions, frailty among survivors converges against a gamma distribution even if
the original distribution is not a gamma distribution.
The use of frailties in the AFT framework has seen increased usage by researchers
over the past fifteen years. These researchers include Pan (2001), Lambert et al.
(2004), Zhang and Peng (2007), and Chen et al. (2013). In this chapter, we investigate
the performance of the individual frailty AFT model using the RSTG distribution as
the baseline survival distribution with a gamma frailty distribution. An expectation-
maximization (EM) algorithm is used for parameter estimation. We apply the
algorithm to an individual frailty model using the New Jersey pediatric nephrotic
syndrome data. A brief example of the applicability of the RSTG distribution in the
correlated frailty model is also presented. We use the correlated frailty model on the
1972 Diabetic Retinopathy study data and compare findings to previously published
findings from this data.
6.2 The Frailty Model
The log-linear formulation of the accelerated failure time model is written as
log Tij = β0 + β1x1ij + β2x2ij + .. . . .+ βpxpij + σεij,
where Tij is the random variable associated with the survival time of the jth
individual in the ith cluster. We introduce ωi to represent either an individual random
effect or the random effect shared by individuals in the ithcluster. The new model is
expressed as
log Tij = β0 + β1x1ij + β2x2ij + .. . . .+ βpxpij + ωi + σεij. (6.1)
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Following the log-linear model formulation in equation (6.1), we express time T as
T = exT β+ω+σε
= exT β ∗ eω ∗ (eεσ)
= exT βeω(T0)
(6.2)
where z = eω is the multiplicative frailty term. A frailty value greater than one
implies an increased hazard of the event of interest occurring while a frailty value less
than one implies a decreased hazard of the event of interest occurring. The variance
of the frailty distribution summarizes the degree of heterogeneity among clusters
(John P. Klein and Moeschberger, 2003).
We assume that T0 = eσε follows the reflected-shifted-truncated-gamma distribu-
tion, with density f ∗(t|α, θ, k) given by equation (4.1), survival function S∗(t|α, θ, k)
given by equation (4.3) and hazard function h∗(t|α, θ, k) given by equation (4.4).
Given the parameter vector Θ = (α, θ,β, k), we express the survival function for
the AFT RSTG frailty model as
SA(t|x,Θ) = P (T ≥ t) = P (exT βeω(T0) ≥ t)
= P (T0 ≥ e−x
T βe−ωt)










)e− (−x+k)θ (−x+ k)α−1dx
= 1− F ∗(g(t))
= S∗(g(t))





) , where g(t) = e
−xT βe−ωt.
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f ∗ (g(t)) · g′(t)
S∗ (g(t))
= h∗ (g(t)) · g′(t)
= e
− (−g(t)+k)








where g′(t) = e−xT βe−ω.
6.3 Parametric Estimation
For a fully parametric model with right-censored observations and no random effects,






The censoring indicator δi is such that
δi =

1 if the event of interest is observed
0 if the event of interest is not observed (event time is right-censored)
.
For the model with random effects ωi, the effects are not known but are assumed
to be independent and identically distributed realizations of a random variable with








Where n is the number of clusters and ni is the number of elements in the ith
cluster.
We assume gamma frailty for the model, specifically zi = eωi ∼ Γ(λ, 1λ). The
density function of z is given by f(z) = 1( 1
λ
)λΓ(λ)z
λ−1e−λz. This distribution has mean
1 and variance 1
λ
.










































where g(tij) = e−x
T
ijβe−ωitij and g′(tij) = e−x
T
ijβe−ωi .
The corresponding log-likelihood function is given by
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For ease of computation, we write the function l(Θ) = l1(α, θ, k, λ)+ l2(β, α, θ, k, λ)
where












































− −g(tij) + k
θ
+ (α− 1) ln (−g(tij) + k) + ln (g′(tij))
}









Without loss of generality, we write l1(α, θ, k, λ) as l1 and l2(β, α, θ, k, λ) as l2.
Due to the unknown random variable ωi, we cannot maximize the logarithm of the
complete likelihood function directly. Following methods similar to those employed
by Chen et al. (2013), we use an EM algorithm. The EM algorithm, first introduced
by Dempster, Laird, and Rubin in 1977, is an iterative optimization algorithm that
alternates between an expectation step (E-step) and a maximization step (M-step).
It is a popular approach for finding maximum likelihood estimates of parameters in
statistical models that depend on unobserved or unknown random variables.
E-step:
The E-step will calculate the conditional expectation of the log-likelihood with respect
to the conditional distribution of the random variable ωi, given the observed data and
the estimates of the parameters. We use equation (6.3) and Bayes’ Theorem to find





where L(ti|ωi) represents the likelihood of the ith event for a fixed ωi, f(ωi) is the
probability of a given value of ωi and P (ti) is the marginal probability of the data
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obtained by integrating L(ti|ωi)f(ωi) with respect to ωi (Collett, 2015) . Ignoring
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Since E (ln (x)) ≤ ln (E(x)) by Jensen’s Inequality, the following relationship also
holds.




















− xTijβ − E(ωi)
}
+ (1− δij) ln
Γ(α)− E
Γ
α, −(e−xTijβtij)(e−ωi) + k
θ

The conditional expectations of ωi and its functions do not have closed form
representations. Based on the conditional distribution of ωi, which is proportional to
(6.5), we sample ωi using a Metropolis-Hastings algorithm. The Metropolis algorithm
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was originally introduced by Metropolis, Rosenbluth, Rosenbluth, Teller, and Teller in
1953 and was generalized by Hastings in 1970. The algorithm generates samples from
a distribution from which direct sampling is difficult. We use the generated samples
to approximate the needed expectations.
M-Step:
The M-step is used to maximize E(l(Θ)) = E(l1) + E(l2)with respect to the unknown
parameters by making use of the quantities found in the E-step. We make use of the
fully specified survival, hazard and density functions.
Estimation procedure
Step 1: Choose initial values α0, β0, θ0, k0, λ0.
Step 2: Sample ωi from the posterior distribution and compute E(ωi),E(eωi) and
E(e−ωi).
Step 3: Estimate new parameter values α∗,β∗, θ∗, k∗, λ∗ by maximizing the likelihood
function.
Step 4: Update the values of α,β, θ, k, λ and repeat steps 2 and 3 until the estimates
converge.
6.4 Application to Pediatric Nephrotic Syndrome
In this section, we revisit the pediatric nephrotic syndrome data from New Jersey.
We use the concept of individual frailty to assess the impact that unmeasured or
non-measurable covariates at the individual level may have on the time to initial
remission. The algorithm discussed in the previous section is used to find the maximum
likelihood estimates and standard errors given in Table 6.1. We compare estimates
from the frailty model to those of the AFT RSTG model without frailty given in
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Table 6.1: RSTG AFT frailty model for pe-
diatric nephrotic syndrome patients in New
Jersey.
Distribution Parameter MLE(se)




Table 5.2. Age remains significant in the presence of individual frailty, but the effect
is less pronounced. The decrease in time to first remission per one year increase in age
is only 4%(95% CI :2%− 6%) after controlling for hematuria status and creatinine
level and accounting for individual frailty. Hematuria status and creatinine level
become significant in the presence of individual frailty. After controlling for age and
creatinine level and accounting for individual frailty, the time to first remission for
pediatric NS patients who exhibit hematuria at diagnosis is 16% longer (95% CI:
9%− 25%) than that of patients who do not exhibit hematuria at diagnosis. After
controlling for age and hematuria status and accounting for individual frailty, the time
to first remission for the pediatric NS patient increases by approximately 12%(95%
CI:8%− 15%) for each 0.1 mg/dL increase in creatinine level at diagnosis. The frailty
variance is significantly larger than 0 in this model and suggests the presence of
significant unobserved heterogeneity at the individual level (λ = 8.192, SE = 0.046).
The effect of hematuria status, which is the most influential of the covariates
assessed on time to initial remission, supports findings of the original study.
6.5 The Correlated Frailty Model for Bivariate Data with
Application to Diabetic Retinopathy
In this section, we evaluate a study on diabetic retinopathy in both juvenile and adult
patients. The Diabetic Retinopathy Study (DRS) was begun by the National Eye
69
Institute in 1972 to study the effectiveness of laser photocoagulation in delaying the
onset of blindness in patients with diabetic retinopathy. Patients were followed over
several years for the occurrence of blindness in the left and right eye. The total study
size was 1742. We consider the 50% sample (N = 197) of both juvenile and adult high
risk patients as defined by DRS criteria that was first analyzed in 1989 by Huster
et al. For each eye, the event of interest was the time from initiation of treatment to
the time when visual acuity dropped below 5/200 for two consecutive visits (defined
as "blindness"). Thus there is a built-in lag time of approximately 6 months (visits
were every 3 months). Survival times in this dataset are the actual time to blindness
in months, minus the minimum possible time to event (6.5 months). Censoring was
caused by death, dropout, or end of the study.
Covariates considered are the laser photocoagulation treatment (0 = xenon, 1
= argon), age (in years), and diabetes diagnosis type (0=juvenile, 1=adult), with
follow-up time given in months. The censoring indicator of each patient (0=censored,
1=blind) is also recorded. The distribution of times is negatively skewed with skewness
coefficient of −0.33. For illustrative purposes, we consider in the first phase of analysis
the times to blindness of the treated eye for each patient. We then account for the
association between eyes of each patient by considering times to blindness in both the
treated and untreated eye using a correlated frailty model.
6.5.1 The RSTG AFT model without frailty
We analyze the DRS data under the accelerated failure time framework with different
distributional assumptions. We consider the covariates laser type, diabetic diagnosis
type and the interaction. The AFT model is given by
log(Ti) = β0 + β1laseri + β2diagnosisi + β3laseri × diagnosisi + σεi, (6.6)
where Ti represents the time to blindness in the treated eye of the ith patient, i = 1, ..., n.
Plots of the deviance residuals for the RSTG AFT model indicate no outliers, but
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Figure 6.1: Deviance residual plots for the RSTG AFT model for the 1972 Diabetic
Retinopathy Study.
Table 6.2: RSTG AFT model for the 1972
Diabetic Retinopathy Study.
Distribution Parameter MLE(se)
RSTG β1 -0.003 (0.422)
β2 0.581 (0.517)
β3 -0.919 (0.641)
suggest slight inadequacies in the model fit as the model tends to predict slightly
longer times to blindness than are observed (Figure 6.1). This may be due to the 73%
censoring rate present in the data set. The RSTG distributional assumption is best of
the compared distributions (Appendix F).
No significant relationships between the time to blindness in the treated eye and
laser type, diabetic diagnosis type or their interaction were detected by the model
(Table 6.2).
6.5.2 The Correlated Gamma Frailty Model using the RSTG distribution
A fundamental consideration in choosing a strategy for the analysis of paired survival
data is whether the correlation within a pair is a nuisance parameter or a parameter
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of intrinsic scientific interest (Huster et al., 1989). In this section, we analyze the
DRS data under the correlated gamma frailty model, a model introduced by Yashin,
Vaupel, and Iachine (1995), using the RSTG survival function. We consider the
time to blindness in both the treated and the untreated eye while adjusting for the
correlation between the left and right eye of each patient. A primary goal of the DRS
study was to assess the effectiveness of the photocoagulation treatment. The DRS
Research Group (1976) reported that either photocoagulation treatment as carried
out in this study was beneficial in reducing severe visual loss over a two-year period.
This data set was later analyzed by Huster et al. (1989) and by Terry M Therneau
and Grambsch (2000) under the proportional hazards framework with semiparametric
Gaussian and gamma frailty models. The DRS data was also analyzed using a shared
inverse Gaussian frailty model by Hanagal and Sharma (2013). Refer to the respective
articles for a complete discussion of the results.
Following the methods discussed by Wienke (2010) for bivariate data, we note the
following representation of the correlated gamma frailty model:
S(t1, t2) =
S1(t1)1−ρS2(t2)1−ρ




where ρ represents the frailty correlation between the left and right eye of each patient,
Sj(t), j = 1, 2 represents the survival functions for the left eye and right eyes, and
σ2 represents the variance of the frailty random variable that is assumed to be the
same for both eyes of each respective patient. Partial derivatives of the bivariate
survival function can be found in the appendix of the Wienke text (2010). We use the
simplifications S(t) = S1(t) = S2(t) and use the RSTG baseline survival function. We
obtain parameter estimates using the method of maximum likelihood (Table 6.3).
The results show a significant positive frailty correlation between the left and
right eyes of each patient. A significant positive correlation was also noted in other
studies (Sahu and Dey, 2000; Hanagal and Sharma, 2013). The inclusion of correlated
frailty in the model produces a change in the significance of the laser type and the
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Table 6.3: The RSTG distri-
bution in a correlated gamma








interaction of laser type and diagnosis type. The risk of blindness is significantly
higher for those treated with the argon treatment as opposed to the xenon treatment
(β1 = 1.288, SE = 0.386) after controlling for diagnosis type. The risk is even more
pronounced when patients are diagnosed with adult diabetes as opposed to juvenile
diabetes (β3 = 1.419, SE = 0.306) . The analysis by Hanagal and Sharma (2013)
and Terry M Therneau and Grambsch (2000) both found a higher risk of blindness
in the argon group and in the adult group individually, but the results were not
statistically significant and did not include an interactive effect. Later analysts
of diabetic retinopathy reported that treatment with xenon was associated with a
higher rate of complications than argon laser and thus recommended argon laser
photocoagulation treatment (Paulus and Blumenkranz, 2013).
6.6 Discussion
The model developed in Section 6.2 can serve as an individual frailty model in which
the frailty represents either an unobserved individual effect or the event dependence of
repeated events for each individual. In either case, the individual serves as a clustering
unit. The developed model can also represent a shared frailty model in which the
frailty is related to a specific characteristic that is shared by a group of individuals.
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The current study makes use the gamma frailty distribution, but other flexible
frailty distributions will be considered in future research. We employ the bootstrap
method for variance estimation of the parameters in the individual frailty model.
Further research is needed to investigate non-simulation based variance estimation
techniques. Parameter estimates were obtained using the method of maximum
likelihood, but the maximum likelihood approach may encounter difficulty when
used in the frailty model (Hanagal et al., 2015). Bayesian approaches for parameter
estimation are also viable options for frailty models (Ibrahim, Chen, and Sinha, 2005;
Santos and Achcar, 2010).
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Chapter 7
Summary and Future Goals
7.1 Summary
Negatively skewed survival data arise in medical research when data cluster near an
upper limit. Simulation studies and comparisons using existing data sets show that
the RSTG distribution performs better than the exponential, generalized gamma,
generalized F, lognormal, log-logistic, Rayleigh, Gompertz and Weibull distributions
when modeling negatively skewed data. The RSTG distribution also performs well
when compared to the Gompertz-sinh family and the logistic-sinh family, which are
two current alternative distributions designed to handle negatively skewed survival
data. The RSTG distribution performs well as a baseline distribution for the general
AFT model, for the AFT frailty model with gamma frailty, and for the correlated
gamma frailty model. The brief example presented on the RSTG distribution used
in a correlated gamma frailty model and applied to the 1972 DRS data had findings
similar to those reported from previous analysis of the data.
Pediatric nephrotic syndrome is a rare disease syndrome that commonly has a
relapsing course. Patients diagnosed with FRNS or SDNS, who previous research
suggests experience a longer time to first remission, pose a greater challenge to
healthcare providers in terms of disease management. Using a meta-analysis of
worldwide studies, we detected a significant relationship between atopy and pediatric
nephrotic syndrome. A study of South Carolina pediatric NS data was conducted
with the RSTG AFT model to determine possible age or seasonal predictors of time to
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first hospital visit after an NS diagnosis, but no significant predictors were found. Our
study of the New Jersey pediatric NS data, conducted with the RSTG AFT model
with individual frailty, shows that higher creatinine levels at diagnosis, presence of
hematuria at diagnosis, and a younger age at diagnosis are indicative of a longer time
to first remission for pediatric NS patients.
7.2 Future Goals
The majority of data on pediatric NS originates in areas outside of the U.S. We will
provide a descriptive analysis of pediatric NS in South Carolina using the HSSC CDW
and continue to search for predictive factors of the syndrome.
Patterns of relapse are a point of interest for pediatric NS patients. Previous studies
suggest that relapse in the first year is a powerful independent predictor of subsequent
relapse regardless of the duration of the illness (Atsushi Takeda, Takimoto, Mizusawa,
and Simoda, 2001). More recent studies have concluded that a decrease in time from
remission of the syndrome to first recurrence of symptoms predicts for a frequently
relapsing course (Sureshkumar et al., 2014). Relapse of NS is almost universally defined
as having proteinuria for three consecutive days after initial remission. Proteinuria can
be detected outside of a clinical setting with the use of prescribed reagent strips for
urinalysis, or in the clinical setting with urinalysis or blood tests. Another factor that
may indicate relapse of the nephrotic syndrome is the presence of edema. While there
is some discrepancy in the literature involving the nature of the edema, it is a condition
that will most likely present itself if the nephrotic syndrome is left untreated and may
be the first indication in the absence of a urinalysis that a relapse of the syndrome
has occurred. Regardless of the method of detection, the relapse will have most likely
occurred before an official clinical diagnosis was made, but within a time frame that
was close to the time of diagnosis. Hence, we expect that the time-to-relapse originates
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from a finite interval over which the distribution of times is negatively skewed. The
RSTG distribution may be suitable to model these interval-censored event times.
Frailty models will be studied further to identify predictive factors of relapse or
remission of the syndrome. A shared frailty model that uses sites such as the Robert
Wood Johnson medical site as a clustering unit will be investigated. A repeated
measures frailty model will be used on time-to-relapse data.
Additional properties of the RSTG distribution will be investigated. Alternative
parameter estimation techniques for the RSTG distribution in the AFT model are
other goals for continued study of this distribution. Also, the efficacy of the RSTG
distribution in the Cox proportional hazards model and the other regression models
will be investigated. The RSTG distribution can be used in any application as a
distribution of choice for modeling event times arising from a negatively skewed
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Steroid Sensitive Nephrotic Syndrome - complete remission within 4 weeks af-
ter initiation of standard corticosteroid therapy
Minimal Change Disease - term used to classify the most common biopsy charac-
terization of the disease
Steroid Responsive Nephrotic Syndrome - also referred to as Steroid Sensitive
Nephrotic Syndrome
Steroid Resistant Nephrotic Syndrome - persistent edema and proteinuria (fail-
ure to achieve complete remission) after 8 weeks of standard corticosteroid
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Appendix C
Derivations of the RSTG Distribution
Functions
C.1 Probability Density Function
The two-parameter gamma distribution is given by
f(t|α, θ) = 1Γ(α)θα e
− t
θ tα−1, 0 < t <∞,
where α > 0 represents the shape parameter and θ > 0 represents the scale parameter.
Reflecting the two-parameter gamma distribution about the y-axis and shifting it
k > 0, the shift parameter, units to the right gives a probability density function of




θ (−t+ k)α−1,−∞ < t < k, α, θ > 0.
The cumulative distribution function of this reflected, shifted gamma distribution is



































Let u = 1
θ
(−x + k). Then du = −1
θ
dx. Changing the limits of integration from
those in terms of x to those in terms of u we have




















for t < k where Γ(a) =
∞∫
0




represents the upper incomplete gamma function.
We now truncate the reflected, shifted gamma distribution on the left at 0,
restricting the interval for t to [0, k]. To achieve a valid probability density function,
we divide by the area that remains after the truncation, F1(k)− F1(0).
The probability density function of the reflected-shifted-truncated-gamma (RSTG)
distribution, then, is




















































)e− (−t+k)θ (−t+ k)α−1 α > 0, θ > 0, 0 ≤ t < k
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C.2 Cumulative Distribution Function
The CDF of the RSTG distribution is given by
















































Let u = 1
θ
(−x + k). Then du = −1
θ
dx. Changing the limits of integration from
those in terms of x to those in terms of u we have



































uα−1 · e−u du
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Hessian Matrix of the RSTG Distribution
The Hessian matrix can be written as























H11 (α, θ, k) H12 (α, θ, k) H13 (α, θ, k)
H21 (α, θ, k) H22 (α, θ, k) H23 (α, θ, k)
H31 (α, θ, k) H32 (α, θ, k) H33 (α, θ, k)
 .
with entries defined as
H11 (α, θ, k) = −n











































































H13 (α, θ, k) = −n

















































































H23 (α, θ, k) = −n





























































































where Γ′(α) = dΓ(α)
dα
= ψ(α)Γ(α), Γ′′(α) = d
2Γ(α)
d2α
























Also, ψ(α) = dΓ(ln(α))
dα
and ψ(α, 1) = dψ(α)
dα
.
We assume the existence of Clairut’s theorem on the equality of mixed partial
derivatives.












This theorem applies to a function f of three or more variables as long as the





Distribution Density Function f(t) Parameters















µ,Q, P ∈ R, σ > 0
F s1 = 2(Q2 + 2P +Qδ)−1
s2 = 2(Q2 + 2P −Qδ)−1
δ = (Q2 + 2P ) 12





−2(Qw − eQw)] σ > 0, µ,Q ∈ R
Gamma w = log(Q2γ)/Q
and γ ∼ Gamma(Q−2, 1)
for t = exp(µ+ σw)



























2b2 b > 0
Weibull λγtγ−1e−λtγ λ, γ > 0
* 0 ≤ t <∞, B(·) is the beta function, γ(·) is the incomplete gamma function
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Appendix F
Simulation Study and Comparative Model Fits
of the RSTG AFT Model
F.1 Simulation Study
For each of 1000 repetitions, we simulate 200 negatively skewed survival times, a
continuous covariate x1 ∼ N(2, 0.12) and a categorical covariate x2 ∼ Bin(2, 0.5).
Following an assumption used by Crowther and Lambert (2013) to simulate biologically
plausible data, we assume administrative censoring to achieve a less than 20% censoring
rate.
We fit an accelerated failure time model to the simulated data using the RSTG,
exponential, generalized gamma, generalized F, lognormal, log-logistic, Rayleigh,
Gompertz and Weibull baseline distributions. We compare them in Table F.1 using
the information theoretic criteria as defined in Chapter 4. The average covariate
parameter estimate, average standard error of the parameter estimate, and average
AIC values of the simulations are reported in Table F.1.
The covariate parameter estimates of the RSTG distribution appear to be more
stable than the parameter estimates given by the comparison models. We note that
while the Gompertz model is commonly used for left skewed distributions, the AIC
value of the RSTG model is more than 10 units lower than that of the Gompertz
model and of other compared models. The RSTG AFT model is the superior model
based on the simulated right-censored data.
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Table F.1: Model fitting results for simulated data.
Distribution Par MLE(se) AIC AICC HQIC CAIC
Exponential β1 0.0442 (1.9220) 648.25 648.29 649.78 651.86
β2 0.0009 (0.9467)
Generalized β1 0.0526 (0.1644) 507.45 507.59 508.98 521.87
F β2 -0.0019 (0.0273)
Generalized β1 0.0224 (0.1429) 500.51 500.62 502.04 511.33
Gamma β2 -0.0039 (0.0232)
Gompertz β1 -0.0066 (0.1529) 476.60 476.68 478.13 483.81
β2 0.0016 (0.0257)
Log-logistic β1 -0.0214 (0.3290) 564.93 565.00 566.46 572.14
β2 0.0028 (0.0563)
Lognormal β1 0.0384 (0.8458) 664.40 664.47 665.93 671.61
β2 -0.0037 (0.1445))
Rayleigh β1 -0.0074 (0.9624) 570.39 570.43 571.92 573.00
β2 -0.0017 (0.4741)
Weibull β1 -0.0052 (0.2540) 533.12 533.19 534.65 540.33
β2 0.0022 (0.0431)
RSTG β1 -0.0230 (0.0242) 465.37 465.44 466.89 472.58
β2 0.0251 (0.0225)
F.2 Comparative Model Fits for HSSC Data
The RSTG distributional assumption is more appropriate than the compared distri-
butional assumptions for the HSSC data based on the AIC and information theoretic
criteria (Table F.2). The AIC value of the RSTG distribution is more than 10 units
lower than the compared distributions.
F.3 Comparative Model Fits for DRS Data
The RSTG AFT model provides the best fit for the DRS data based on the AIC and
other information theoretic criteria of the compared distributions (Table F.3). The
AIC value of the RSTG distribution is more than 10 units lower than the compared
distributions.
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Table F.2: Model fitting results for the HSSC pediatric nephrotic syndrome
data.
Distribution Par MLE(se) AIC AICC HQIC CAIC




Generalized β1 0.071 (0.006) 188.16 189.05 189.44 209.05
F β2 -0.079 (0.063)
β3 -0.363 (0.088)
β4 -0.474 (0.087)
Generalized β1 0.070 (0.002) 184.50 185.26 185.78 202.78
Gamma β2 -0.085 (0.035)
β3 -0.358 (0.038)
β4 0.469 (0.048)

























Table F.3: Model fitting results for treated eyes of patients in the 1972 Diabetic
Retinopathy Study.
Distribution Par MLE(se) AIC AICC HQIC CAIC
Exponential β1 0.201 (0.002) 647.18 647.26 648.84 668.60
β2 -0.495 (-0.417)
β3 -0.030 (0.579)
Generalized β1 -0.348 (0.565) 640.20 640.33 641.86 674.47
F β2 0.802 (0.560)
β3 -0.180 (0.831)
Generalized β1 -0.538 (0.485) 637.42 637.54 639.08 667.41
Gamma β2 0.636 (0.517)
β3 -0.029 (0.750)
Gompertz β1 0.201 (0.335) 653.09 653.17 654.75 674.51
β2 -0.495 (0.417)
β3 -0.030 (0.578)
Log-logistic β1 0.223 (0.459) 647.22 647.30 648.88 668.64
β2 -0.694 (0.544)
β3 0.015 (0.760)
Lognormal β1 0.286 (0.476) 643.52 643.62 645.18 669.22
β2 -0.721 (0.550)
β3 0.028 (0.775)
Rayleigh β1 -0.123 (0.168) 727.53 727.61 729.19 748.95
β2 0.235 (0.208)
β3 0.073 (0.289)
Weibull β1 0.244 (0.425) 649.03 649.11 650.69 670.45
β2 -0.620 (0.532)
β3 -0.009 (0.732)
RSTG β1 - 0.003 (0.422) 599.96 600.08 601.62 629.94
β2 0.581 (0.517)
β3 -0.919 (0.641)
105
